ALC Stock Analysis: Alcon | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 29.168m CHF | 12M Return: -9.6% | CH0432492467 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 75.3M
EPS Trend: 88.6%
Qual. Beats: 2
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alcon Inc. (ALC) is a Switzerland-headquartered global eye care company that operates through two segments: Surgical and Vision Care. The Surgical segment provides equipment, instrumentation, diagnostics, intraocular lenses (IOLs), and other implantables, along with consumables used in cataract, vitreoretinal, and refractive (LASIK) procedures. The Vision Care segment offers daily disposable, reusable, and color-enhancing contact lenses, plus ocular health products spanning dry eye, allergies, glaucoma, contact lens care, ocular vitamins, and redness relievers.
The company is one of the largest pure-play ophthalmic medical device and consumer eye care businesses in the world, competing primarily in the global eye care industry alongside Bausch + Lomb and Johnson & Johnson Vision. Demand for its products is structurally supported by aging demographics, rising rates of cataracts, presbyopia, and refractive errors, and increasing access to vision correction in emerging markets. Founded in 1945 and headquartered in Geneva, Alcon was formerly known as Alcon Universal S.A. before adopting its current name in December 2001.
- Premium IOL adoption lifts Surgical segment growth
- Vision Care pricing squeezed by Bausch + Lomb and J&J
- Strong Swiss franc creates persistent FX translation headwinds
| Net Income: 1.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.34 > 1.0 |
| NWC/Revenue: 32.17% < 20% (prev 38.72%; Δ -6.55% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.27b > Net Income 1.03b |
| Net Debt (4.38b) to EBITDA (2.33b): 1.88 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (488.7m) vs 12m ago -1.85% < -2% |
| Gross Margin: 56.83% > 18% (prev 55.13%; Δ 1.70% > 0.5%) |
| Asset Turnover: 34.44% > 50% (prev 31.94%; Δ 2.50% > 0%) |
| Interest Coverage Ratio: 5.34 > 6 (EBIT TTM 1.11b / Interest Expense TTM 207.4m) |
| DSRI: 0.97 (Receivables 2.11b/2.02b, Revenue 10.8b/10.0b) |
| GMI: 0.97 (GM 55.13% / 56.83%) |
| AQI: 0.97 (AQ_t 0.62 / AQ_t-1 0.64) |
| SGI: 1.07 (Revenue 10.8b / 10.0b) |
| TATA: -0.04 (NI 1.03b - CFO 2.27b) / TA 31.2b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of August 26, 2026, the stock is trading at CHF 58.92 with a total of 721,280 shares traded. Over the past week, the price has changed by +0.07%, over one month by +5.71%, over three months by +11.13% and over the past year by -9.58%.
Current recommended Stop Loss: 54.90 (which is 6.8% or 2.8 ATR below the current price).
Alcon has no consensus analysts rating.
Market Cap USD = 36.4b (29.2b CHF * 1.2494 CHF.USD)
P/E Trailing = 56.3925
P/E Forward = 20.9205
P/S = 2.6856
P/B = 1.609
P/EG = 1.4952
Revenue TTM = 10.8b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 2.33b USD
Long Term Debt = 4.16b USD (from longTermDebt, two quarters ago)
Short Term Debt = 652.8m USD (from shortTermDebt, last quarter)
Debt = 5.84b USD (from shortLongTermDebtTotal, last quarter) + Leases 528.0m
Net Debt = 4.38b USD (calculated: Debt 5.84b - CCE 1.46b)
Enterprise Value = 40.8b USD (36.4b + Debt 5.84b - CCE 1.46b)
Interest Coverage Ratio = 5.34 (Ebit TTM 1.11b / Interest Expense TTM 207.4m)
EV/FCF = 23.84x (Enterprise Value 40.8b / FCF TTM 1.71b)
FCF Yield = 4.19% (FCF TTM 1.71b / Enterprise Value 40.8b)
FCF Margin = 15.89% (FCF TTM 1.71b / Revenue TTM 10.8b)
Net Margin = 9.53% (Net Income TTM 1.03b / Revenue TTM 10.8b)
Gross Margin = 56.83% ((Revenue TTM 10.8b - Cost of Revenue TTM 4.65b) / Revenue TTM)
Gross Margin QoQ = 59.33% (prev 56.36%)
Tobins Q-Ratio = 1.31 (Enterprise Value 40.8b / Total Assets 31.2b)
Interest Expense / Debt = 3.55% (Interest Expense 207.4m / Debt 5.84b)
Taxrate = 13.28% (98.1m / 738.7m)
NOPAT = 959.7m (EBIT 1.11b * (1 - 13.28%))
Current Ratio = 2.09 (Total Current Assets 6.64b / Total Current Liabilities 3.18b)
Debt / Equity = 0.27 (Debt 5.84b / totalStockholderEquity, last quarter 21.7b)
Debt / EBITDA = 1.88 (Net Debt 4.38b / EBITDA 2.33b)
Debt / FCF = 2.56 (Net Debt 4.38b / FCF TTM 1.71b)
Total Stockholder Equity = 22.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.28% (Net Income 1.03b / Total Assets 31.2b)
RoE = 4.67% (Net Income TTM 1.03b / Total Stockholder Equity 22.0b)
RoCE = 4.23% (EBIT 1.11b / Capital Employed (Equity 22.0b + L.T.Debt 4.16b))
RoIC = 3.41% (NOPAT 959.7m / Invested Capital 28.1b)
WACC = 5.92% (E(36.4b)/V(42.3b) * Re(6.37%) + D(5.84b)/V(42.3b) * Rd(3.55%) * (1-Tc(0.13)))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.45 | Cagr: -0.71%
[DCF] Terminal Value 76.18% ; FCFF base≈1.67b ; Y1≈1.76b ; Y5≈2.05b
[DCF] Fair Price = 56.30 (EV 31.6b - Net Debt 4.38b = Equity 27.2b / Shares 483.4m; r=8.35% [WACC [floored]]; 5y FCF grow 5.82% → 2.50% )
EPS Correlation: 88.60 | EPS CAGR: 7.50% | SUE: 2.47 | # QB: 2
Revenue Correlation: 98.98 | Revenue CAGR: 5.22% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.89 | Chg30d=+0.00% | Revisions=-50% | Analysts=15
EPS current Year (2026-12-31): EPS=3.50 | Chg30d=+0.80% | Revisions=-30% | GrowthEPS=+13.9% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=4.38 | Chg30d=+0.82% | Revisions=-22% | GrowthEPS=+25.2% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -42% (up=4, down=12)